Here's what you need to know about the four CFTR (cystic fibrosis transmembrane conductance regulator) modulators.
The following is a collection of information and news about Trikafta®, the
Trikafta®, a highly effective modulator therapy initially approved by the FDA on October 21, 2019, treats the underlying cause of CF. The following are commonly asked questions about Trikafta.
Drugs that target the underlying defect in the cystic fibrosis transmembrane conductance regulator (
Theratyping matches therapies, or medications, to specific types of mutations. The primary goal of theratyping is to identify which mutations respond to certain CFTR modulators, thereby helping people with rare CFTR mutations gain access to already approved modulators quickly and safely.